In a new paper, PPTA dives into the critical nature of plasma-derived medicines (PDMPs) for the lives of patients. Plasma is a limited, human-donated starting material with long manufacturing timelines and a complex supply chain. Thus, national or short-term stockpiling is not a sustainable solution to address shortages or sudden spikes in demand. Instead, the focus of EU and member states should be on strengthening the supply continuity of plasma across the EU with sustainable plasma collection and regulatory alignment for plasma availability for manufacturing. Click to read more on this important topic.